NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today notes the announcement issued by Sarborg Limited ("Sarborg") regarding the filing of a U.S. provisional patent application relating to its proprietary AI Signature Agent.

CDT holds a 20% equity stake in Sarborg and views this filing as an important step in strengthening and formalising Sarborg's intellectual property position.

Sarborg announced that a provisional patent application was filed with the United States Patent and Trademark Office on February 12, 2026, and has been assigned United States Patent Application No. 63/981,801. The application relates to Sarborg's Signature Agent architecture and its methodology for encoding and analysing biological, chemical and industrial signatures to generate ranked, intelligence-driven outputs.

"As a 20% shareholder, we view the filing of Sarborg's provisional patent application as an important milestone in the development and protection of its proprietary technology," said Dr. Andrew Regan, Chief Executive of CDT. "We believe continued advancement of Sarborg's intellectual property supports the scalability of its Signature Agent across multiple sectors and enhances its long-term growth profile."

A copy of Sarborg's full announcement is available at Sarborg Files U.S. Provisional Patent Application for its AI Signature Agent or at www.sarborg.com.

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ:CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company's common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors

CDT Equity Inc.

Info@cdtequity.com

CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent